Home » Stocks » Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. (ALDX)

Stock Price: $6.77 USD 0.22 (3.36%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $6.79 +0.02 (0.30%) Aug 4, 6:35 PM

Stock Price Chart

Key Info

Market Cap 201.69M
Revenue (ttm) n/a
Net Income (ttm) -55.07M
Shares Out 34.37M
EPS (ttm) -1.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $6.77
Previous Close $6.55
Change ($) 0.22
Change (%) 3.36%
Day's Open 6.49
Day's Range 6.45 - 6.89
Day's Volume 520,364
52-Week Range 1.48 - 8.05

More Stats

Market Cap 201.69M
Enterprise Value 155.15M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 34.37M
Float 25.88M
EPS (basic) -1.99
EPS (diluted) -1.99
FCF / Share -1.63
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 629,119
Short Ratio 0.34
Short % of Float 1.99%
Beta 2.11
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.00
Revenue n/a
Operating Income -55.28M
Net Income -55.07M
Free Cash Flow -47.72M
Net Cash 46.53M
Net Cash / Share 1.56
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -45.74%
ROE -90.32%
ROIC -174.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$27.20*
(301.77% upside)
Low
15.0
Current: $6.77
High
34.0
Target: 27.20
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-------
Operating Income-63.07-39.70-22.49-18.70-11.99-7.27-3.68
Net Income-60.83-38.89-22.34-18.70-12.09-5.1913.06
Shares Outstanding27.1121.6915.9211.358.633.820.32
Earnings Per Share-2.24-1.79-1.40-1.65-1.40-3.09-17.61
Operating Cash Flow-44.98-29.86-19.22-15.15-9.31-4.78-1.71
Capital Expenditures-0.01-0.26-0.02-0.01-0.09-0.01-
Free Cash Flow-44.99-30.12-19.25-15.16-9.40-4.79-1.71
Cash & Equivalents73.3693.6042.9524.9127.598.533.26
Total Debt14.75-1.341.321.291.251.27
Net Cash / Debt58.6193.6041.6123.6026.307.271.99
Assets75.5295.0944.1725.1928.208.793.74
Liabilities27.448.474.573.543.332.505.65
Book Value48.0886.6239.6021.6524.886.28-40.22
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aldeyra Therapeutics, Inc.
Country United States
Employees 15
CEO Todd C. Brady

Stock Information

Ticker Symbol ALDX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALDX
IPO Date May 2, 2014

Description

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.